CFO Kyri K. Van Hoose Discloses 9% Stake After $750K Private Placement Purchase
DRMA sits 24% above its 52-week low of $1.1 on light trading volume (0.1× avg).
Summary
Dermata Therapeutics' CFO, Kyri K. Van Hoose, has disclosed a 9.0% beneficial ownership stake, including a $750,099 personal investment in a December 2025 private placement, signaling strong executive confidence amidst ongoing dilutive financing.
Key Events · Ownership and Investor Activity · DRMA
-
CFO Discloses 9.0% Beneficial Ownership
Kyri K. Van Hoose, CFO, now beneficially owns 384,352 shares, representing 9.0% of the company's common stock.
-
Significant Personal Investment
The ownership includes 122,549 shares and warrants for 245,098 shares acquired in a December 2025 private placement, totaling a $750,099 investment from personal funds.
-
Warrants Became Exercisable
The disclosure follows shareholder approval on May 27, 2026, which made the warrants acquired in the private placement exercisable.
-
Warrant Exercise Price Amended
An existing warrant for 7,874 shares held by the CFO had its exercise price amended from $12.70 to $2.04, significantly benefiting the insider.
Analysis · DRMA · Life Sciences
Chief Financial Officer Kyri K. Van Hoose has disclosed a significant 9.0% beneficial ownership stake in Dermata Therapeutics, stemming from a $750,099 private placement purchase made with personal funds in December 2025. This substantial investment by a key executive, equivalent to nearly 14% of the company's market cap, signals strong conviction in the company's future, especially given the recent history of dilutive financing and going concern warnings. The disclosure follows shareholder approval on May 27, 2026, which made warrants acquired in the private placement exercisable.
At the time of this filing, DRMA was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $1.10 to $8.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.